

1 **Hospital admission with non-alcoholic fatty liver disease is associated with**
2 **increased all-cause mortality independent of cardiovascular risk factors**

3
4
5 Jake P. Mann^{1,2,3}, Paul Carter^{3,4}, Matthew J. Armstrong⁵, Hesham K Abdelaziz^{6,7}, Hardeep
6 Uppal³, Billal Patel⁶, Suresh Chandran⁸, Ranjit More⁶, Philip N. Newsome^{9,10¶}, Rahul
7 Potluri^{3¶*}

8
9
10 ¹Institute of Metabolic Science, University of Cambridge, UK

11 ²Department of Paediatrics, University of Cambridge, Cambridge, UK

12 ³ACALM Study Unit in collaboration with Aston Medical School, Aston University,
13 Birmingham, UK

14 ⁴Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge,
15 Cambridge, UK

16 ⁵Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

17 ⁶Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, UK

18 ⁷Department of Cardiovascular Medicine, Ain Shams University Hospital, Cairo, Egypt

19 ⁸Department of Medicine, Pennine Acute Hospitals NHS Trust, Manchester, UK

20 ⁹National Institute for Health Research Liver Biomedical Research Unit at University
21 Hospitals Birmingham NHS Foundation Trust and the University of Birmingham,
22 Birmingham, UK

23 ¹⁰Centre for Liver Research, Institute of Immunology and Immunotherapy, University of
24 Birmingham, Birmingham, UK

25
26 **Corresponding author:** research that has not been certified by peer review and should not be used to guide clinical practice.

27 Dr. Jake P Mann
28 MRC Epidemiology Unit
29 Level 3, Institute of Metabolic Science
30 Addenbrooke's Hospital
31 Cambridge, CB2 0QQ
32 jm2032@cam.ac.uk
33 T: +44 1223 330315

34

35 †These authors contributed equally to this work.

36

37 **Author contributions:**

38 **JPM:** Conceptualization, formal analysis, Writing – Original Draft Preparation, Writing –
39 Review & Editing. **PC:** Data curation, formal analysis, Writing – Review & Editing. **MA:**
40 Conceptualization, Writing – Review & Editing. **HKA, HU, BP, SC, RM:** Data Curation,
41 Project Administration, Resources, Writing – Review & Editing. **PNN & RP:**
42 Conceptualization, Project Administration, Supervision, Writing – Review & Editing.

43

44

45

46 **Abbreviations:** ACALM – Algorithm for Comorbidities, Associations, Length of stay and
47 Mortality; CV – cardiovascular; HR – hazard ratio; ICD-10 – International Classification of
48 Disease, 10th edition; NAFLD – non-alcoholic fatty liver (disease); NASH – non-alcoholic
49 steatohepatitis

50

51

52

53 **Abstract**

54

55 Background

56 Non-alcoholic fatty liver disease (NAFLD) is common and strongly associated with the
57 metabolic syndrome. Though NAFLD may progress to end-stage liver disease, the top
58 cause of mortality in NAFLD is cardiovascular disease (CVD). Most of the data on liver-
59 related mortality in NAFLD derives from specialist liver centres. We aimed to assess
60 mortality in NAFLD when adjusting for CVD in a 'real world' cohort of inpatients.

61

62 Methods

63 Retrospective study of hospitalised patients with 14-years follow-up. NAFL (non-alcoholic
64 fatty liver), non-alcoholic steatohepatitis (NASH), and NAFLD-cirrhosis groups were defined
65 by ICD-10 codes using ACALM methodology. Cases were age-/sex-matched 1:10 with non-
66 NAFLD hospitalised patients from the ACALM registry. All-cause mortality was compared
67 between groups using cox regression adjusted for CVD and metabolic syndrome risk
68 factors.

69

70 Results

71 We identified 1238 patients with NAFL, 105 with NASH and 1235 with NAFLD-cirrhosis.
72 There was an increasing burden of cardiovascular disease with progression from NAFL to
73 NASH to cirrhosis. After adjustment for demographics, metabolic syndrome components
74 and cardiovascular disease, patients with NAFL, NASH, and cirrhosis all had increased all-
75 cause mortality (HR 1.3 (CI 1.1-1.5), HR 1.5 (CI 1.0-2.3) and HR 3.5 (CI 3.3-3.9),
76 respectively). Hepatic decompensation (NAFL HR 8.0 (CI 6.1-10.4), NASH HR 6.5 (2.7-
77 15.4) and cirrhosis HR 85.8 (CI 72-104)), and hepatocellular carcinoma were increased in
78 all NAFLD groups.

79

80 Conclusion

81 There is a high burden of cardiovascular disease in NAFLD-cirrhosis patients. From a large
82 “real-life” non-specialist registry of hospitalized patients, NAFLD patients have increased
83 overall mortality and rate of liver-related complications compared to controls after adjusting
84 for cardiovascular disease.

85

86 Keywords

87 Non-alcoholic fatty liver disease, cardiovascular outcomes, cirrhosis, hepatocellular
88 carcinoma, heart failure

89

90

91 Introduction

92

93 Non-alcoholic fatty liver disease is the most common liver disease in Europe[1] and is
94 strongly associated with all features of the metabolic syndrome[2]. The majority of NAFLD
95 patients have simple steatosis (non-alcoholic fatty liver, NAFL) and only a minority with non-
96 alcoholic steatohepatitis (NASH), with or without fibrosis. However a small, but significant
97 proportion do progress to end-stage liver disease[3].

98

99 NAFLD is thought to be associated with increased all-cause and cardiovascular mortality[4–
100 6]. It has been established that fibrosis is the main predictor of long-term liver-related
101 morbidity in NAFLD[7–9] and that patients with NASH but no fibrosis have a similar outcome
102 to those with NAFL and no fibrosis. However, these studies included biopsy-proven patients
103 in specialist clinics and therefore there is likely significant ascertainment bias in estimating
104 rates of hepatic complications. The natural history of NAFLD and its impact upon clinical
105 services is an important topic that divides expert opinion[10,11].

106

107 Cardiovascular disease (CVD) is the commonest cause of mortality in patients with
108 NAFLD[9]. A recent large-scale analysis strongly suggests that this is due to prevalence of
109 classical CVD risk factors such as type 2 diabetes and dyslipidaemia[12]. Insulin resistance
110 is thought to be the primary driver linking all these features of the metabolic syndrome. In
111 response to the positive energy balance of obesity, subcutaneous adipose becomes
112 dysfunctional and there is expansion of visceral white adipocytes, which are less insulin
113 sensitive and have a higher basal rate of lipolysis[13]. Elevated insulin and increased
114 substrate delivery to the liver promotes hepatic steatosis by driving increased *de novo*
115 lipogenesis without increasing glucose uptake[14]. Cumulatively, this results in a rise in
116 circulating triglycerides, impaired low-density lipoprotein clearance, and higher serum

117 glucose. Hepatic steatosis is also thought to alter the composition of secreted lipoparticles
118 [15].

119

120 A further increasingly important consideration is the burden of cardiovascular co-morbidity
121 in patients with end-stage NAFLD for whom transplantation is an option[16]. There is
122 currently limited data on the prevalence of CVD in patients with NAFLD cirrhosis[17]. CVD
123 events are common post-transplant sequelae and chronic kidney disease is linked to
124 reduced graft survival[18].

125

126 Whilst several previous natural history studies have included comparison to age- and
127 gender-matched control populations, they have been unable to control for CVD[19–21].
128 Therefore, it remains unclear whether NAFLD is associated with increased all-cause
129 mortality after correction for cardiac and metabolic disease risk factors.

130

131 We aimed to first describe the burden of cardiovascular disease across the NAFLD disease
132 spectrum: non-alcoholic fatty liver (NAFL, or simple steatosis), non-alcoholic steatohepatitis
133 (NASH, steatosis plus histological inflammation), and NAFLD-cirrhosis (end-stage fibrosis)
134 and whether NAFL and NASH are associated with increased all-cause mortality in a real life
135 cohort of hospitalised UK patients from the ACALM registry, after correction for CVD and
136 metabolic risk factors.

137

138

139 **Materials and Methods**

140

141 The study was conducted as a retrospective cohort study of adult patients in England during
142 2000-2013 who were admitted to 7 different hospitals with naturalistic follow-up. All available
143 data was included. Tracing of anonymised patients was performed using the ACALM
144 (Algorithm for Comorbidities, Associations, Length of stay and Mortality) study protocol to
145 develop the ACALM registry and has been previously described by our group[22–27].
146 Briefly, medical records were obtained from local health authority computerized Hospital
147 Activity Analysis register, which is routinely collected by all NHS hospitals. This provides
148 fully anonymized data on hospital admissions and allows for the long-term tracing of patients
149 at an individual hospital. The ACALM protocol uses using International Classification of
150 Disease, 10th edition (ICD-10) and Office of Population Censuses and Surveys Classification
151 of Interventions and Procedures (OPCS-4) coding systems to trace patients. This data was
152 obtained separately for the seven included hospitals. Similar data could be obtained through
153 national Hospital Episode Statistics or from any local Hospital Activity Analysis register.

154

155 ICD-10 codes were used to identify patients with NAFL (non-alcoholic fatty liver, K76.0),
156 NASH (non-alcoholic steatohepatitis, K75.8), and NAFLD-cirrhosis (cryptogenic cirrhosis,
157 K74.6). Patients with a history of alcohol excess (F10) were excluded. Where a patient was
158 coded with both NAFL and NASH, they were included in the NASH group. Patients coded
159 with both NAFL and NAFLD-cirrhosis, or NASH and NAFLD-cirrhosis, were included in the
160 cirrhosis group. As per UK practice, the diagnosis of NAFL, NASH, or NAFLD-cirrhosis were
161 made according to clinical judgement and the latest guidelines but the results of the
162 investigations used to derive the diagnoses were not available. An age- and sex-matched
163 control group (with no liver-related diagnoses) was identified from the same ACALM registry
164 and matched 10:1 to patients with NAFLD diagnoses.

165

166 All of these patients were then assessed for the presence of several cardiovascular co-
167 morbidities and risk factors, including: congestive heart failure (CHF, I150.0), atrial fibrillation
168 (I48), and non-insulin dependent diabetes mellitus (NIDDM, E11), chronic kidney disease
169 (N18), obesity (E66.0), myocardial infarction (I21-I22), ischaemic heart disease (I20-25),
170 ischaemic stroke (I63.9), hyperlipidaemia (E78.5), hypertension (I10), and peripheral
171 vascular disease (I73.9). Patients were also assessed for liver-related events: hepatocellular
172 carcinoma (C22.9), hepatic failure (K72), oesophageal varices (I85), portal hypertension
173 (K76.6), splenomegaly (R16.1), and ascites (R18). A combined 'hepatic decompensation or
174 failure' score was generated from the sum of all non-malignant liver-related events. Inclusion
175 of hepatic encephalopathy (K72.9) or variceal bleeding (I98.3, I98.8, I85.9) did not identify
176 any additional patients. Jaundice was not included due to identification of patients with
177 obstructive (non-hepatic) jaundice.

178

179 Vital status (alive or deceased) on 31st March 2013 was determined by record linkage to the
180 National Health Tracing Services (NHS strategic tracing service) and was received along
181 with the raw data; this was used to calculate all-cause mortality and survival.

182

183 The first admission to hospital treatment was chosen as index admission, follow-up of
184 patients continued until 31st March 2013. Confidentiality of information was maintained in
185 accordance with the UK Data Protection Act. The patient data included was fully anonymous
186 and non-identifiable when received by the authors, and collected routinely by the hospitals.
187 Therefore, according to local research ethics policies we were not required to seek formal
188 ethical approval for this study.

189

190 Data analysis was performed using SPSS version 20.0 (SPSS Inc. Chicago, IL) and
191 GraphPad Prism version 7.0. Clinical outcomes were compared between groups using chi-
192 squared tests. Cox regression analysis was used to determine adjusted hazard ratios for
193 overall mortality in NAFL, NASH, and cirrhosis groups relative to control. Cox regression
194 was performed twice, first accounting for variations in demographics (age, gender, ethnicity),
195 and then accounting for demographics plus obesity, NIDDM, CHF, ischaemic stroke,
196 myocardial infarction, chronic kidney disease, peripheral vascular disease, hypertension,
197 hyperlipidaemia, ischaemic heart disease, and atrial fibrillation. Participants with incomplete
198 data were excluded. Kaplan-Meier curves were used to determine survival in patients.
199 Multivariate logistic regression was used to determine hazard ratios for hepatic
200 failure/decompensation and hepatocellular carcinoma, adjusted for demographics (age,
201 gender, ethnicity). $P < 0.05$ was taken as significant. No additional sensitivity analyses were
202 performed.

203

204

205

206

207

208

209 **Results**

210

211 2,578 patients were identified with NAFLD-spectrum diagnoses, of which 1,238 had NAFL,
212 105 had NASH and 1,235 NAFLD-cirrhosis (Table 1). They were matched to 25,780
213 hospitalised in-patient controls. The median duration of follow-up for each group was: control
214 5.3 years, NAFL 4.6 years, NASH 4.4 years, and cirrhosis 2.8 years (range 1 day - 14 years
215 for all).

216

217

218 **Table 1. Demographics, mortality, and liver outcomes** for control, NAFL, NASH and
219 NAFLD-cirrhosis patients.

Clinical outcome Number (%)	Control (n=25,780)	NAFL (n=1,238)	NASH (n=105)	Cirrhosis (n=1,235)
Mean age (\pm standard error)	55 \pm 15	51 \pm 14	52 \pm 17	59 \pm 14
Male	14,570 (56.5%)	690 (55.7%)	57 (54.3%)	710 (57.5%)
Caucasian	20,626 (80.0%)	960 (77.5%)	87 (82.9%)	943 (76.4%)
South Asian	1,693 (6.6%)	150 (12.1%)	6 (5.7%)	151 (12.2%)
All-cause mortality	3,852 (14.9%)	174 (14.1%)	23 (21.9%)	664 (53.8%)
Overall mortality adjusted for demographic characteristics (HR with 95% CI)	-	1.4 (1.2-1.6)	2.0 (1.3-3.0)	4.1 (3.7-4.4)

Overall mortality adjusted for demographics, CV risk factors, and CV disease (HR with 95% CI)	-	1.3 (1.1-1.5)	1.5 (1.0-2.3)	3.5 (3.3-3.9)
Hepatic failure/decompensation, n (%)	232 (0.9%)	85 (6.9%)	6 (5.7%)	551 (44.6%)
Adj. HR (95% CI)	-	8.0 (6.1-10.4)	6.5 (2.7-15.4)	85.8 (72-102)
Hepatocellular carcinoma, n (%)	49 (0.2%)	14 (1.1%)	1 (1.0%)	152 (12.3%)
Adj. HR (95% CI)	-	3.8 (2.0-7.5)	2.6 (0.3-21.0)	65.4 (45-94)

220 Clinical outcomes for patients during a 14-year study period. Adjusted hazard ratios of
 221 overall mortality for NAFL, NASH, and cirrhosis are relative to control. Adjustment for
 222 demographic characteristics included gender, age and ethnicity. Adjustment for
 223 cardiovascular risk factors and cardiovascular disease includes: obesity, type 2 diabetes
 224 mellitus, CHF, ischaemic stroke, myocardial infarction, chronic kidney disease, peripheral
 225 vascular disease, hypertension, hyperlipidaemia, ischaemic heart disease, and atrial
 226 fibrillation. Adjusted hazard ratios for liver outcomes are corrected for demographic
 227 characteristics. Adj., adjusted; CI = confidence interval; CV = cardiovascular; HR = hazard
 228 ratio.

229

230

231 Patients with NAFL and NASH had a higher prevalence of metabolic risk factors and
 232 cardiovascular disease than hospitalised controls (Table 2). Hyperlipidaemia, type 2
 233 diabetes mellitus (T2DM), and obesity were similar between NAFL and NASH groups.
 234 Compared to the NAFL group, patients with cirrhosis were more likely to have T2DM (20%

235 NAFL vs. 30% cirrhosis, $p < 0.001$) but had a lower prevalence of hyperlipidaemia (12% NAFL
236 vs. 4.8% cirrhosis, $p < 0.001$).

237

238

239 **Table 2. Cardiovascular disease burden across the NAFLD spectrum.**

Clinical outcome	Control	NAFL	NASH	Cirrhosis
Number (%)	(n=25,780)	(n=1238)	(n=105)	(n=1235)
Obesity	318 (1.2)	89 (7.2) ^{##}	11 (10.5)	41 (3.3) ^{***}
Type 2 Diabetes	2,414 (9.4)	246 (19.9) ^{##}	21 (21.9)	372 (30.1) ^{***}
Hyperlipidaemia	2,065 (8.0)	149 (12.0) ^{##}	19 (18.1)	59 (4.8) ^{***}
Congestive Heart Failure	897 (3.5)	46 (3.7)	11 (10.5) [‡]	81 (6.6) ^{**}
Atrial fibrillation	1,212 (4.7)	61 (4.9)	9 (8.6)	102 (8.3) ^{***}
Chronic Kidney Disease	522 (2.0)	33 (2.7)	5 (4.8)	81 (6.6) ^{***}
Ischaemic heart disease	3,027 (11.7)	121 (9.8)	11 (10.5)	152 (12.3) [*]
Myocardial infarction	966 (3.7)	24 (1.9)	4 (3.8)	27 (2.2)
Ischaemic stroke	521 (2.0)	34 (2.5)	0	34 (2.8)
Hypertension	5,808 (22.5)	365 (29.5) ^{##}	37 (35.2)	333 (27.0)
Peripheral vascular disease	393 (1.5)	13 (1.1)	3 (2.9)	16 (1.3)
All-cause mortality	3,841 (14.9)	175 (14.1)	23 (21.9)[†]	664 (53.8)^{***}

240 Crude rates of mortality, metabolic, and cardiovascular outcomes for NAFL, NASH, and
241 cirrhosis, patients during a 14-year study period.

242 For control vs. NAFL: [#] $p < 0.05$, ^{##} $p < 0.001$ For NAFL vs. NASH: [†] $p < 0.05$, [‡] $p < 0.001$. For NAFL
243 vs. cirrhosis: ^{*} $p < 0.05$, ^{**} $p < 0.001$, ^{***} $p < 0.0001$. p values were calculated using chi squared
244 tests.

245


246

247 There was an increasing burden of cardiovascular co-morbidity with more advanced liver
248 disease. Compared to the control group, patients with NAFL had increased hypertension
249 (30% NAFL vs. 23% control, $p < 0.001$.) Patients with NASH had a higher prevalence of heart
250 failure than those with NAFL (11% vs. 4%, $p = 0.001$). The cirrhosis group showed higher
251 prevalence of heart failure, atrial fibrillation, CKD, and ischaemic heart disease, compared
252 to the NAFL group.

253

254 Unadjusted 14-year all-cause mortality was 14.9% for patients in the control group, 14.1%
255 for patients with NAFL, 21.9% for patients with NASH and 53.8% for those with NAFLD-
256 cirrhosis (Fig 1). After adjustment for age, gender and ethnicity, all-cause mortality hazard
257 ratios (HR) were higher in all NAFLD groups compared to the control group (Table 1). After
258 adjustment for cardiovascular factors all-cause mortality was still elevated compared to the
259 control group: NAFL HR 1.3 (CI 1.1-1.5), NASH HR 1.5 (1.0-2.3) and NAFLD-cirrhosis HR
260 3.5 (CI 3.3-3.9). All cause-mortality was similar between NAFL and NASH groups.

261



262

263 **Figure 1.** Kaplan-Meier survival curves for NAFL, NASH, and cirrhosis patients compared
 264 to non-NAFLD patients admitted to hospital.

265

266

267 The prevalence of hepatic events (hepatic failure and development of HCC) was higher in
 268 all groups of patients with NAFLD and was similar between NAFL and NASH groups. This
 269 observation remained after correction for age, sex, and ethnicity: for hepatic failure or
 270 decompensation, relative to control, NAFL HR 8.0 (CI 6.1-10.4), NASH HR 6.5 (2.7-15.4)
 271 and NAFLD-cirrhosis HR 85.8 (CI 72-104, Table 1); and for HCC, relative to control, NAFL
 272 HR 3.8 (2.0-7.5), NASH HR 2.6 (0.3-21.0), NAFLD-cirrhosis HR 65.4 (45-94).

273 Discussion

274

275 This study provides important non-specialist “real life” data amongst hospitalised patients
276 demonstrating an increased mortality for patients with NAFLD, irrespective of fibrosis, even
277 after adjustment for CVD. The size of the cohort and lack of link to specialist liver centres
278 reduces likelihood of bias. These data will help inform healthcare demand for this cohort of
279 patients, complementing modelling estimates[28,29]. In addition, we have highlighted the
280 burden of cardiovascular disease in patients with NAFLD-cirrhosis, which highlights a
281 particular issue for transplantation. Whilst all participants in our cohort were hospitalised,
282 which may increase their risk of future clinical events, so were the controls, thus the
283 comparisons between groups remain valid.

284

285 The strong association between NAFLD and cardiovascular disease has been well
286 established[30,31]. Relationships have been identified between NAFLD and heart
287 failure[32], atrial fibrillation[33], hypertension[34], stroke[35], chronic kidney disease[36],
288 and coronary artery disease. NAFLD has even been linked to increased mortality in acute
289 heart failure[37]. However strong observational data from a large European meta-analysis
290 suggests that NAFLD is not causal in acceleration of cardiovascular disease[12]. Our data
291 highlights the particularly increased prevalence towards cirrhosis. Indeed, hypertension has
292 recently been highlighted as an independent risk factor for advanced fibrosis in NAFLD. A
293 further consideration is whether heart failure contributes to accelerated fibrosis in
294 NAFLD[38], though causality is difficult to establish.

295

296 Previous studies with biopsy-defined cohorts have been smaller, did not adjust for
297 cardiovascular diagnoses[9,20], and found no difference in mortality between participants
298 with NAFLD and no fibrosis and controls. Kim *et al.* used NHANES data to stratify patients

299 by non-invasive fibrosis scores, and again found no increase in mortality in patients with
300 ultrasound-defined NAFLD, after correction for diabetes and hypertension[19]. This may be
301 accounted for by differences in the ethnicity of the cohort and also the general, rather than
302 specialist, nature of our population.

303

304 NAFLD may itself be a marker of sub-clinical cardiovascular disease. For example,
305 increased carotid intima media thickness has been found in adolescents with NAFLD[39].
306 This is mechanistically plausible as hepatic steatosis occurs (in part) in response to
307 peripheral insulin resistance and elevated substrate delivery from lipolysis of adipose tissue.
308 Steatosis itself then contributes to systemic insulin resistance[40]. Therefore, in this
309 analysis, despite adjusting for metabolic covariates and cardiovascular risk factors, elevated
310 mortality may reflect the sub-clinical nature of atherosclerosis associated with NAFLD, even
311 at an early stage.

312

313 Given the shared disease mechanisms and clinical outcomes for NAFLD and cardiovascular
314 disease, these data suggest a common framework for treatment. Weight loss is the only
315 established treatment strategy for NAFLD[41] and there is data suggesting that specific
316 dietary regimens (including the Mediterranean diet) are beneficial[42]. The same lifestyle
317 interventions and aggressive risk factor modification will dual impact on reducing
318 cardiovascular[43,44] and hepatic events.

319

320 Whilst we were not able to determine cause of death or admission in our cohort, we were
321 able to determine that liver decompensation events were increased in all groups relative to
322 the control group.

323

324 This study is limited by its retrospective design and the use of generic coding, which did not
325 provide information on how the diagnosis was obtained i.e. imaging, liver function tests, or
326 liver biopsy and we were unable to identify whether NAFLD was the cause of admission or
327 an existing co-morbidity in cases. Therefore, differences between the NAFL and NASH
328 groups should be interpreted with this in mind. However, coding improvements in recent
329 years along with standardised diagnosis of NAFLD in the UK means that the impact of
330 inaccurate coding is likely to be low. Published studies suggest that only 2-10%[1] of the
331 NAFLD groups may be affected and thus have minimal impact on the results observed in
332 this study. The use of ICD-10 codes for the exclusion of other causes of liver dysfunction
333 (for example, viral hepatitis) and patients with a history of alcohol consumption may have
334 also contributed to inaccurate coding. However, such biases have been limited from our
335 previous study looking at the association between cardiovascular and respiratory conditions
336 [30]. There is likely to be a degree of under coding of NAFLD, especially as clinical
337 awareness of NAFLD was not optimal at the beginning of the data capture[47].

338

339 In conclusion, these results contribute to our understanding of co-morbidity, mortality and
340 liver decompensation in patients with NAFLD spectrum disease and demonstrate that the
341 increase in mortality occurs independently of known cardiovascular risk factors.

342

343

344 **References**

345

- 346 1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global
347 epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of
348 prevalence, incidence, and outcomes. *Hepatology*. 2016;64: 73–84.
349 doi:10.1002/hep.28431
- 350 2. Stefan N, Häring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis,
351 cardiometabolic consequences, and treatment strategies. *Lancet Diabetes
352 Endocrinol*. 2018;8587: 1–12. doi:10.1016/S2213-8587(18)30154-2
- 353 3. Angulo P, Kleiner DE, Dam-Larsen S, Adams L a, Bjornsson ES,
354 Charatchoenwittaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is
355 Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver
356 Disease. *Gastroenterology*. 2015;149: 389-397.e10.
357 doi:10.1053/j.gastro.2015.04.043
- 358 4. Musso G, Gambino R, Maurizio C, Pagano G. Meta-analysis: Natural history of non-
359 alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests
360 for liver disease severity. *Ann Med*. 2011;43: 617–649.
- 361 5. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al.
362 Nonalcoholic fatty liver disease is a novel predictor cardiovascular disease. *World J
363 Gastroenterol*. 2007;13: 1579–1584. doi:10.3748/wjg.v13.i10.1579
- 364 6. Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, et al.
365 Cardiovascular disease, cancer, and mortality among people with type 2 diabetes
366 and alcoholic or nonalcoholic fatty liver disease hospital admission. *Diabetes Care*.
367 2018;41: 341–347. doi:10.2337/dc17-1590
- 368 7. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis
369 stage but not NASH predicts mortality and time to development of severe liver

- 370 disease in biopsy-proven NAFLD. *J Hepatol.* 2017; doi: 10.1016/j.jhep.2017.07.027.
371 doi:10.1016/j.jhep.2017.07.027
- 372 8. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of
373 mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and
374 meta-analysis. *Hepatology.* 2017;65: 1557–1565. doi:10.1002/hep.29085
- 375 9. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES,
376 Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is
377 associated with long-term outcomes of patients with nonalcoholic fatty liver disease.
378 *Gastroenterology.* 2015;149: 389-397.e10. doi:10.1053/j.gastro.2015.04.043
- 379 10. Rowe IA. Too much medicine: overdiagnosis and overtreatment of non-alcoholic
380 fatty liver disease. *Lancet Gastroenterol Hepatol.* 2018;3: 66–72.
381 doi:10.1016/S2468-1253(17)30142-5
- 382 11. Ratziu V. The painful reality of end-stage liver disease in NASH. *Lancet*
383 *Gastroenterol Hepatol.* 2018;3: 8–10.
- 384 12. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell
385 D, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial
386 infarction and stroke: findings from matched cohort study of 18 million European
387 adults. *Bmj.* 2019;367: l5367. doi:10.1136/bmj.l5367
- 388 13. Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic
389 and Hepatic Diseases. *Cell Metab.* 2017. doi:10.1016/j.cmet.2017.08.002
- 390 14. Sanders FWB, Acharjee A, Walker C, Marney L, Roberts LD, Imamura F, et al.
391 Hepatic steatosis risk is partly driven by increased de novo lipogenesis following
392 carbohydrate consumption. *Genome Biol.* 2018;19: 79. doi:10.1186/s13059-018-
393 1439-8
- 394 15. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus,
395 cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol.* 2013;10: 330–

- 396 344. doi:10.1038/nrgastro.2013.41
- 397 16. Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic
398 Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver
399 Transplantation. *Transplantation*. 2018; doi: 10.1097/TP.0000000000002484 [Epub
400 ahead of pr. doi:10.1097/TP.0000000000000000
- 401 17. Kilaru SM, Quarta G, Popov V. Diabetes, Heart Failure, and Chronic Kidney Disease
402 are Risk Factors for Nafld-Related Cirrhosis: A Nationwide Analysis.
403 *Gastroenterology*. 2017;152: S688–S689. doi:10.1016/S0016-5085(17)32415-0
- 404 18. Molnar MZ, Joglekar K, Jiang Y, Cholankeril G, Abdul MKM, Kedia S, et al.
405 Association of Pre-Transplant Renal Function with Liver Graft and Patient Survival
406 after Liver Transplantation in Patients with Nonalcoholic Steatohepatitis. *Liver
407 Transplant*. 2018; doi: 10.1002/lt.25367 [Epub ahead of print]. doi:10.1002/lt.25367
- 408 19. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis
409 markers and mortality among adults with nonalcoholic fatty liver disease in the
410 United States. *Hepatology*. 2013;57: 1357–1365. doi:10.1002/hep.26156
- 411 20. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis
412 stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33
413 years of follow-up. *Hepatology*. 2015;61: 1547–1554. Available:
414 <http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:No+Title#0>
- 415 21. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al.
416 Long-term follow-up of patients with NAFLD and elevated liver enzymes.
417 *Hepatology*. 2006;44: 865–73. doi:10.1002/hep.21327
- 418 22. Sangha J, Natalwala A, Mann J, Uppal H, Mummadi SM, Haque A, et al. Co-
419 morbidities and mortality associated with intracranial bleeds and ischaemic stroke.
420 *Int J Neurosci*. 2015;125: 256–263. doi:10.3109/00207454.2014.930463
- 421 23. Uppal H, Chandran S, Potluri R. Risk factors for mortality in Down syndrome. *J*

- 422 Intellect Disabil Res. 2015; [Epub ahead of print]. doi:10.1111/jir.12196
- 423 24. Potluri R, Baig M, Mavi JS, Ali N, Aziz A, Uppal H, et al. The role of angioplasty in
424 patients with acute coronary syndrome and previous coronary artery bypass grafting.
425 Int J Cardiol. 2014;176: 760–3. doi:10.1016/j.ijcard.2014.07.097
- 426 25. Carter P, Rai G, Aziz A, Mann J, Chandran S, Uppal H, et al. Trends of
427 cardiovascular disease amongst psychiatric patients between 2001 and 2012 in
428 Greater Manchester, UK. Int J Cardiol. 2014;173: 573–574.
- 429 26. Ziff OJ, Carter PR, McGowan J, Uppal H, Chandran S, Russell S, et al. The interplay
430 between atrial fibrillation and heart failure on long-term mortality and length of stay:
431 Insights from the, United Kingdom ACALM registry. Int J Cardiol. 2018;252: 117–
432 121. doi:10.1016/j.ijcard.2017.06.033
- 433 27. Ziaei F, Zaman M, Rasoul D, Gorantla RS, Bhayani R, Shakir S, et al. The
434 prevalence of atrial fibrillation amongst heart failure patients increases with age. Int J
435 Cardiol. 2016;214: 410–411. doi:10.1016/j.ijcard.2016.03.198
- 436 28. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The
437 economic and clinical burden of nonalcoholic fatty liver disease in the United States
438 and Europe. Hepatology. 2016;64: 1577–1586. doi:10.1002/hep.28785
- 439 29. Estes C, Razavi H, Loomba R, Younossi ZM, Sanyal AJ. Modeling the epidemic of
440 nonalcoholic fatty liver disease demonstrates an exponential increase in burden of
441 disease. Hepatology. 2017; doi:10.1002/hep.29466. doi:10.1002/hep.
- 442 30. Wu S, Wu F, Yingying D, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty
443 liver disease with major adverse cardiovascular events: A systematic review and
444 meta-analysis. Sci Rep. 2016;6: 33386. doi:10.1038/srep33386
- 445 31. Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Askling J, et al. Cardiovascular
446 risk factors in non-alcoholic fatty liver disease. Liver Int. 2018; 1–8.
447 doi:10.1111/liv.13973

- 448 32. Wijarnpreecha K, Lou S, Panjawatnan P, Cheungpasitporn W, Pungpapong S,
449 Lukens FJ, et al. Association between diastolic cardiac dysfunction and nonalcoholic
450 fatty liver disease: A systematic review and meta-analysis. *Dig Liver Dis.* 2018;50:
451 1166–1175. doi:10.1016/j.dld.2018.09.004
- 452 33. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, et al. Non-
453 Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial
454 Fibrillation in Patients with Type 2 Diabetes. *PLoS One.* 2013;8.
455 doi:10.1371/journal.pone.0057183
- 456 34. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of
457 existing fatty liver, over five years of follow-up, and risk of incident hypertension. *J*
458 *Hepatol.* 2014;60: 1040–1045. doi:10.1016/j.jhep.2014.01.009
- 459 35. Alexander KS, Zakai NA, Lidofsky SD, Callas PW, Judd SE, Tracy RP, et al. Non-
460 alcoholic fatty liver disease, liver biomarkers and stroke risk: The reasons for
461 geographic and racial differences in stroke cohort. *PLoS One.* 2018;13: 1–13.
462 doi:10.1371/journal.pone.0194153
- 463 36. Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM. Chronic Kidney
464 Disease is Independently Associated with Increased Mortality in Patients with Non-
465 alcoholic Fatty Liver Disease. *Liver Int.* 2018; doi: 10.1111/liv.13992 [Epub ahead of
466 print]. doi:10.1111/liv.13992
- 467 37. Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, et al. Non-alcoholic
468 fatty liver disease and increased risk of all-cause mortality in elderly patients
469 admitted for acute heart failure. *Int J Cardiol.* 2018;265: 162–168.
470 doi:10.1016/j.ijcard.2018.04.129
- 471 38. Colli A, Pozzoni P, Berzuini A, Gerosa A, Canovi C, Molteni EE, et al.
472 Decompensated Chronic Heart Failure: Increased Liver Stiffness Measured by
473 Means of Transient Elastography. *Radiology.* 2010;257: 872–878.

- 474 doi:10.1148/radiol.10100013
- 475 39. Gökçe S, Atbinici Z, Aycan Z, Cınar HG, Zorlu P. The relationship between pediatric
476 nonalcoholic fatty liver disease and cardiovascular risk factors and increased risk of
477 atherosclerosis in obese children. *Pediatr Cardiol*. 2013;34: 308–15.
478 doi:10.1007/s00246-012-0447-9
- 479 40. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: Integrating
480 signaling pathways and substrate flux. *J Clin Invest*. 2016;126: 12–22.
481 doi:10.1172/JCI77812
- 482 41. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease:
483 Improvement in liver histological analysis with weight loss. *Hepatology*. 2004;39:
484 1647–1654. doi:10.1002/hep.20251
- 485 42. Properzi C, O'Sullivan TA, Sherriff JL, Ching HL, Jeffrey GP, Buckley RF, et al. *Ad*
486 *libitum* Mediterranean and Low Fat Diets both Significantly Reduce Hepatic
487 Steatosis: a Randomized Controlled Trial. *Hepatology*. 2018;68: 1741–1754.
488 doi:10.1002/hep.30076
- 489 43. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its
490 components, and cardiovascular disease. *Am J Med*. 2015;128: 229–238.
491 doi:10.1016/j.amjmed.2014.10.014
- 492 44. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and
493 cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An
494 update of the 1997 American Heart Association Scientific Statement on obesity and
495 heart disease from the Obesity Committee of the Council on Nutrition, Physical.
496 *Circulation*. 2006;113: 898–918. doi:10.1161/CIRCULATIONAHA.106.171016
- 497 45. Zeb I, Li D, Budoff MJ, Katz R, Lloyd-Jones D, Agatston A, et al. Nonalcoholic Fatty
498 Liver Disease and Incident Cardiac Events the Multi-Ethnic Study of Atherosclerosis.
499 *J Am Coll Cardiol*. 2016;67: 1965–1966. doi:10.1016/j.jacc.2016.01.070

- 500 46. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver
501 disease and risk of incident cardiovascular disease: A meta-analysis. *J Hepatol.*
502 2016;65: 589–600. doi:10.1016/j.jhep.2016.05.013
- 503 47. Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function
504 tests dealt with in primary care? Audit of yeild and impact. *BMJ.* 2001;322: 276–278.

505

506 **Financial support**

507 JPM is supported by a Wellcome Trust Fellowship (216329/Z/19/Z,
508 <https://wellcome.ac.uk>). The funders had no role in study design, data collection and
509 analysis, decision to publish, or preparation of the manuscript.

510

511 **Conflict of interest**

512 The authors have no conflicts of interest to declare.

513

514

515